Clinical Study to Assess the Safety and Efficacy of ACV Moringa Effervescent Tablet Intake on Wei… (NCT07098624) | Clinical Trial Compass
Not Yet RecruitingNot Applicable
Clinical Study to Assess the Safety and Efficacy of ACV Moringa Effervescent Tablet Intake on Weight Management in Overweight and Class I Obese Study Participants
66 participantsStarted 2025-07-24
Plain-language summary
A Randomized, Double-Blind, Placebo-Controlled, Two-Arm, Single-Centre, Clinical Study to Evaluate the Safety and Efficacy of Intake of ACV Moringa on the Degree of Weight Change in Overweight and Class I Obese Study Participants
Who can participate
Age range
18 Years – 65 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
. Age: 18- 65 years (both inclusive) at the time of consent.
. Sex: Males and non-pregnant/non-lactating females (preferably equal number of males and females).
. Females of childbearing potential must have a self-reported negative urine pregnancy.
. Female of childbearing potential must have a reported negative pregnancy during screening and the end of the study
. Subject is in good general health as determined by the Investigator on the basis of medical history.
. Subjects who are classified as overweight (BMI 25.0-29.9 kg/m²) or as having Class I obesity (BMI 30.0-34.9 kg/m²).
. Subjects with a total body fat percentage exceeding 25% for men and 30% for women using Bioimpedance test.
. Subject is willing to forgo liposuction procedures or any weight loss therapy 3 months prior to and for the duration of the study.
Exclusion criteria
. Subjects BMI is between less than 25 and greater than 35 kg/m2.
. Subjects having past or present history or clinically significant findings indicating cardiovascular disease, type 2 diabetes mellitus, hypertension, endocrine, pulmonary, neurological or psychological disorders, hypo or hyperthyroidism and renal disorders.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Change in body weight using calibrated weighing machine
Timeframe: Day 01 (pre-treatment), Day 45 (+2 days), and Day 90 (+2 days)
. Subjects with a history of gastrointestinal disorders, including chronic gastritis, gastric discomfort, or any diagnosed gastrointestinal conditions.
. Subjects having drug and alcohol abuse.
. Smokers and tobacco users.
. Subjects having more than 5 kg variation in body weight within 3 months before study entry.
. Subjects using other weight loss medications, as well as stimulants, laxatives or diuretics taken solely for the purpose of weight loss.
. Undergone surgery before 30 days of screening or planning to undergo surgery within the study period.